US Edition
Change to NHS Drug Analysis on the Table to Stave Off US Tariffs – Reports
The UK plans to raise the National Institute for Health and Care Excellence spending threshold by 25% to avoid US tariffs, risking billions more NHS drug spending, experts warn.
- Experts warn that pressure from Donald Trump to increase UK drug prices could harm the NHS budget and patient care.
- The Nuffield Trust advises the government against increasing the NICE threshold, stating that it could lead to higher overall drug spending without better health outcomes.
- Pharmaceutical companies, including AstraZeneca and Merck, may halt investments in the UK if drug prices are not raised as Trump demands.
- Increasing investment in new drugs without improving existing services could lead to a net loss of health benefits for the population.
20 Articles
20 Articles
NHS prices to skyrocket because Starmer caved to Trump
The NHS is the world’s largest publicly-funded health service, and this gives it tremendous bargaining power with big pharma. Unfortunately, our current prime minister Keir Starmer is significantly weaker than the NHS when it comes to bargaining, which is why we’re facing a higher burden on health spending: Trump pressure to hike UK drug prices could cost NHS billions. Corporate profits will increase. NHS budget will buy less. People to pay hig…
Streeting and Reeves in Cabinet battle over cost of NHS drugs under Trump deal
Ministers are locked in a battle over how to pay for the funding of price rises in NHS medicines under a trade deal with Donald Trump. Keir Starmer’s Government is in “advanced discussions” with Washington over a plan to increase the amount the NHS pays pharmaceutical firms for the drugs, in return for the US not imposing tariffs on the sector. The proposals would see the limit at which a drug is deemed to be cost-effective for the NHS raised. T…
Coverage Details
Bias Distribution
- 54% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
